SG11202105302PA - Dll3-targeting multispecific antigen-binding molecules and uses thereof - Google Patents
Dll3-targeting multispecific antigen-binding molecules and uses thereofInfo
- Publication number
- SG11202105302PA SG11202105302PA SG11202105302PA SG11202105302PA SG11202105302PA SG 11202105302P A SG11202105302P A SG 11202105302PA SG 11202105302P A SG11202105302P A SG 11202105302PA SG 11202105302P A SG11202105302P A SG 11202105302PA SG 11202105302P A SG11202105302P A SG 11202105302PA
- Authority
- SG
- Singapore
- Prior art keywords
- dll3
- binding molecules
- multispecific antigen
- targeting
- targeting multispecific
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020062326 | 2020-03-31 | ||
PCT/JP2021/013460 WO2021200898A1 (en) | 2020-03-31 | 2021-03-30 | Dll3-targeting multispecific antigen-binding molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202105302PA true SG11202105302PA (en) | 2021-11-29 |
Family
ID=77855554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202105302PA SG11202105302PA (en) | 2020-03-31 | 2021-03-30 | Dll3-targeting multispecific antigen-binding molecules and uses thereof |
Country Status (18)
Country | Link |
---|---|
US (3) | US11274151B2 (en) |
EP (1) | EP4126969A1 (en) |
JP (2) | JP7085666B2 (en) |
KR (2) | KR102505383B1 (en) |
CN (1) | CN115397866A (en) |
AR (1) | AR121695A1 (en) |
AU (1) | AU2021250186A1 (en) |
BR (1) | BR112022019498A2 (en) |
CA (1) | CA3173587A1 (en) |
CL (1) | CL2022002624A1 (en) |
CO (1) | CO2022015305A2 (en) |
CR (1) | CR20220541A (en) |
IL (1) | IL296803A (en) |
MX (1) | MX2022012091A (en) |
PE (1) | PE20230077A1 (en) |
SG (1) | SG11202105302PA (en) |
TW (2) | TW202325741A (en) |
WO (1) | WO2021200898A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113307873A (en) | 2013-11-11 | 2021-08-27 | 中外制药株式会社 | Antigen binding molecules comprising altered antibody variable regions |
US11952422B2 (en) | 2017-12-05 | 2024-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 |
US11667713B2 (en) | 2017-12-28 | 2023-06-06 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
BR112022017526A2 (en) * | 2020-03-31 | 2022-10-18 | Chugai Pharmaceutical Co Ltd | METHOD FOR PRODUCING MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES |
CN115397866A (en) | 2020-03-31 | 2022-11-25 | 中外制药株式会社 | DLL 3-targeted multispecific antigen-binding molecules and uses thereof |
WO2023053272A1 (en) * | 2021-09-29 | 2023-04-06 | Chugai Seiyaku Kabushiki Kaisha | Uses of dll3-targeting multispecific antigen-binding molecules |
WO2023164474A1 (en) | 2022-02-23 | 2023-08-31 | Amgen Inc. | Cancer treatment targeting dll3 |
CN116813784B (en) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | Antibodies targeting DLL3 and uses thereof |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0328966Y2 (en) | 1987-10-16 | 1991-06-20 | ||
AP257A (en) | 1991-04-26 | 1993-06-03 | Surface Active Ltd | A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy. |
AU6235294A (en) | 1993-02-02 | 1994-08-29 | Scripps Research Institute, The | Methods for producing polypeptide binding sites |
US5981478A (en) | 1993-11-24 | 1999-11-09 | La Jolla Cancer Research Foundation | Integrin-binding peptides |
JP4332581B2 (en) | 1998-02-19 | 2009-09-16 | 旭化成株式会社 | Human delta-3 |
JP4139508B2 (en) | 1998-02-19 | 2008-08-27 | 旭化成株式会社 | Human delta 3 |
US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
ES2694002T3 (en) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polypeptide comprising an Fc region of variant human IgG1 |
JP2002540763A (en) | 1999-02-10 | 2002-12-03 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 33 human secreted proteins |
JP2003507029A (en) | 1999-08-19 | 2003-02-25 | カイロン コーポレイション | Notch receptor ligands and uses thereof |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
AU2001280471A1 (en) | 2000-08-11 | 2002-02-25 | Eli Lilly And Company | Novel secreted proteins and their uses |
DE60124912T2 (en) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimeric, single chain, tandem Fv antibodies |
AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
US20070224201A1 (en) | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20040115204A1 (en) | 2002-12-11 | 2004-06-17 | Fanger Gary R. | Antibodies to treat cancer |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
DE602005027309D1 (en) | 2004-01-16 | 2011-05-19 | Regeneron Pharma | FOR ACTIVATING RECEPTORS CAPABLE FUSION POLYPEPTIDES |
US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
EP1797127B1 (en) | 2004-09-24 | 2017-06-14 | Amgen Inc. | Modified fc molecules |
JP5553963B2 (en) | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | Methods for refolding recombinant antibodies |
AU2005299355A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Llc | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
CN101123983A (en) | 2004-10-27 | 2008-02-13 | 米迪缪尼股份有限公司 | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
CN101098891B (en) | 2005-01-05 | 2014-05-21 | F-星生物技术研究与开发有限公司 | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
CA2596248A1 (en) | 2005-01-31 | 2006-08-10 | Vaxinnate Corporation | Method to identify polypeptide toll-like receptor (tlr) ligands |
WO2006106905A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
RU2008129028A (en) | 2005-12-16 | 2010-01-27 | Дженентек, Инк. (Us) | METHOD FOR DIAGNOSTIC, FORECASTING AND TREATMENT OF GLIOMA |
EP2216339A1 (en) | 2006-01-16 | 2010-08-11 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis |
MX2008013057A (en) | 2006-04-14 | 2009-04-07 | Trubion Pharmaceuticals Inc | Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions. |
CN103435697A (en) | 2006-05-15 | 2013-12-11 | 航道生物技术有限责任公司 | Neutralizing antibodies to influenza viruses |
AT503889B1 (en) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | MULTIVALENT IMMUNE LOBULINE |
EP2078731A4 (en) | 2006-10-20 | 2012-08-01 | Forerunner Pharma Res Co Ltd | Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient |
KR101589759B1 (en) | 2007-04-03 | 2016-01-29 | 암젠 리서치 (뮌헨) 게엠베하 | Cross-species-specific cd3-epsilon binding domain |
JP2010524851A (en) | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | Species-specific binding domains |
JP5718637B2 (en) | 2007-06-21 | 2015-05-13 | マクロジェニクス,インコーポレーテッド | Covalently bonded diabody and its use |
CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
US8580927B2 (en) | 2008-01-31 | 2013-11-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineered antibody constant domain molecules |
WO2009124931A2 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
JP5796831B2 (en) | 2008-09-03 | 2015-10-21 | ジェネンテック, インコーポレイテッド | Multispecific antibody |
DK2334705T3 (en) | 2008-09-26 | 2017-03-27 | Ucb Biopharma Sprl | BIOLOGICAL PRODUCTS |
CN106432503B (en) | 2008-12-19 | 2020-03-06 | 宏观基因有限公司 | Covalent diabodies and uses thereof |
RS62387B1 (en) | 2010-01-29 | 2021-10-29 | Chugai Pharmaceutical Co Ltd | Anti-dll3 antibody |
JP5889181B2 (en) | 2010-03-04 | 2016-03-22 | 中外製薬株式会社 | Antibody constant region variants |
WO2011127350A1 (en) | 2010-04-09 | 2011-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
RU2624027C2 (en) | 2010-04-23 | 2017-06-30 | Дженентек, Инк. | Heteromultimeric proteins production |
JP6167040B2 (en) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Design of stable heterodimeric antibodies with mutations in the Fc domain |
WO2012064792A2 (en) | 2010-11-09 | 2012-05-18 | Altimab Therapeutics, Inc. | Protein complexes for antigen binding and methods of use |
BR112013013311A2 (en) | 2010-11-30 | 2017-09-19 | Chugai Pharmaceutical Co Ltd | cytotoxicity-inducing therapeutic agent |
US9469685B2 (en) | 2011-01-10 | 2016-10-18 | Emory University | Antibodies directed against influenza |
AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
UA117072C2 (en) | 2011-05-21 | 2018-06-11 | Макродженікс, Інк. | CD3-Binding Molecule Able to Bind to CD3 HUMAN AND NON-HUMAN CD3 |
TWI687441B (en) | 2011-06-30 | 2020-03-11 | 中外製藥股份有限公司 | Heterodimerized polypeptide |
WO2013010955A1 (en) | 2011-07-15 | 2013-01-24 | Morphosys Ag | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
HUE038225T2 (en) | 2011-08-23 | 2018-10-29 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
RU2605390C2 (en) | 2011-08-23 | 2016-12-20 | Рош Гликарт Аг | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
MX359384B (en) | 2011-10-11 | 2018-09-25 | Genentech Inc | Improved assembly of bispecific antibodies. |
EP2768863B1 (en) | 2011-10-20 | 2017-09-27 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-cd22 chimeric antigen receptors |
EP3093293A1 (en) | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Anti dll3 antibodies and methods of use thereof |
JPWO2013180200A1 (en) | 2012-05-30 | 2016-01-21 | 中外製薬株式会社 | Target tissue specific antigen binding molecule |
JP6628966B2 (en) | 2012-06-14 | 2020-01-15 | 中外製薬株式会社 | Antigen binding molecule containing an altered Fc region |
CN105102618B (en) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | heterodimerization polypeptide |
WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
CN113307873A (en) | 2013-11-11 | 2021-08-27 | 中外制药株式会社 | Antigen binding molecules comprising altered antibody variable regions |
KR20170008202A (en) | 2014-02-21 | 2017-01-23 | 애브비 스템센트알엑스 엘엘씨 | Anti-dll3 antibodies and drug conjugates for use in melanoma |
MX2016011627A (en) | 2014-03-12 | 2016-11-29 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates. |
US20170274072A1 (en) | 2014-03-26 | 2017-09-28 | Tohoku University | Bispecific antibody targeting human epidermal growth factor receptor |
TWI726842B (en) | 2014-04-07 | 2021-05-11 | 日商中外製藥股份有限公司 | Immune activation antigen binding molecule |
WO2016016415A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
TW201609812A (en) | 2014-07-31 | 2016-03-16 | 安美基研究(慕尼黑)公司 | Optimized cross-species specific bispecific single chain antibody constructs |
EP2982692A1 (en) * | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
KR20170052600A (en) | 2014-09-12 | 2017-05-12 | 제넨테크, 인크. | Cysteine engineered antibodies and conjugates |
TWI831044B (en) | 2014-11-11 | 2024-02-01 | 日商中外製藥股份有限公司 | Antigen-binding molecules, pharmaceutical compositions containing antigen-binding molecules, and methods of manufacturing and selecting antigen-binding molecules |
WO2016194992A1 (en) | 2015-06-05 | 2016-12-08 | 中外製薬株式会社 | Combined use of immune activators |
LT3115376T (en) | 2015-07-10 | 2018-11-12 | Merus N.V. | Human cd3 binding antibody |
TW202346349A (en) * | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
PE20181890A1 (en) | 2016-05-02 | 2018-12-11 | Hoffmann La Roche | CONTORSBODY - A MONOCATENARIO DIANA LEAGUE |
CN109963871A (en) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | Multivalence and multi-epitope Antibody and application method with agonist activity |
TWI829628B (en) | 2016-12-19 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy with targeted 4-1bb (cd137) agonists |
BR112019007267A2 (en) | 2016-12-20 | 2019-07-09 | Hoffmann La Roche | anti-cd20 / anti-cd3 bispecific antibody, pharmaceutical product, pharmaceutical composition comprising a anti-cd20 / anti-cd3 bispecific antibody, use of anti-cd20 / anti-cd3 bispecific antibody combination and a 4-1bb agonist and method of treatment or retardation of cancer progression in patients |
CA3060856A1 (en) | 2017-05-05 | 2018-11-08 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
US11952422B2 (en) | 2017-12-05 | 2024-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 |
US11667713B2 (en) | 2017-12-28 | 2023-06-06 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
SG11202101152QA (en) | 2018-08-03 | 2021-03-30 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
WO2020067419A1 (en) | 2018-09-28 | 2020-04-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously |
SG11202102882YA (en) | 2018-09-28 | 2021-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule comprising altered antibody variable region |
CA3168510A1 (en) | 2020-02-05 | 2021-08-12 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing and/or enriching recombinant antigen-binding molecules |
CN115397866A (en) | 2020-03-31 | 2022-11-25 | 中外制药株式会社 | DLL 3-targeted multispecific antigen-binding molecules and uses thereof |
BR112022017526A2 (en) | 2020-03-31 | 2022-10-18 | Chugai Pharmaceutical Co Ltd | METHOD FOR PRODUCING MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES |
-
2021
- 2021-03-30 CN CN202180026335.9A patent/CN115397866A/en active Pending
- 2021-03-30 KR KR1020217035325A patent/KR102505383B1/en active IP Right Grant
- 2021-03-30 CR CR20220541A patent/CR20220541A/en unknown
- 2021-03-30 TW TW112110624A patent/TW202325741A/en unknown
- 2021-03-30 BR BR112022019498A patent/BR112022019498A2/en unknown
- 2021-03-30 EP EP21781866.5A patent/EP4126969A1/en active Pending
- 2021-03-30 AR ARP210100792A patent/AR121695A1/en unknown
- 2021-03-30 AU AU2021250186A patent/AU2021250186A1/en active Pending
- 2021-03-30 WO PCT/JP2021/013460 patent/WO2021200898A1/en active Application Filing
- 2021-03-30 JP JP2021056413A patent/JP7085666B2/en active Active
- 2021-03-30 MX MX2022012091A patent/MX2022012091A/en unknown
- 2021-03-30 CA CA3173587A patent/CA3173587A1/en active Pending
- 2021-03-30 PE PE2022002150A patent/PE20230077A1/en unknown
- 2021-03-30 TW TW110111556A patent/TWI799824B/en active
- 2021-03-30 KR KR1020237006522A patent/KR20230035138A/en active Application Filing
- 2021-03-30 US US17/216,981 patent/US11274151B2/en active Active
- 2021-03-30 SG SG11202105302PA patent/SG11202105302PA/en unknown
- 2021-03-30 IL IL296803A patent/IL296803A/en unknown
-
2022
- 2022-02-14 US US17/670,917 patent/US11718672B2/en active Active
- 2022-06-06 JP JP2022091351A patent/JP2022122972A/en active Pending
- 2022-09-27 CL CL2022002624A patent/CL2022002624A1/en unknown
- 2022-10-27 CO CONC2022/0015305A patent/CO2022015305A2/en unknown
-
2023
- 2023-06-29 US US18/343,850 patent/US20240010725A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022122972A (en) | 2022-08-23 |
CR20220541A (en) | 2022-11-28 |
KR20220100520A (en) | 2022-07-15 |
US20210301016A1 (en) | 2021-09-30 |
TW202325741A (en) | 2023-07-01 |
TWI799824B (en) | 2023-04-21 |
CO2022015305A2 (en) | 2022-11-08 |
US11274151B2 (en) | 2022-03-15 |
TW202204409A (en) | 2022-02-01 |
AR121695A1 (en) | 2022-06-29 |
EP4126969A1 (en) | 2023-02-08 |
US11718672B2 (en) | 2023-08-08 |
KR20230035138A (en) | 2023-03-10 |
JP7085666B2 (en) | 2022-06-16 |
US20220251201A1 (en) | 2022-08-11 |
CN115397866A (en) | 2022-11-25 |
CA3173587A1 (en) | 2021-10-07 |
US20240010725A1 (en) | 2024-01-11 |
WO2021200898A1 (en) | 2021-10-07 |
IL296803A (en) | 2022-11-01 |
KR102505383B1 (en) | 2023-03-02 |
MX2022012091A (en) | 2022-10-13 |
AU2021250186A1 (en) | 2022-12-01 |
PE20230077A1 (en) | 2023-01-11 |
JP2021159081A (en) | 2021-10-11 |
BR112022019498A2 (en) | 2022-11-16 |
CL2022002624A1 (en) | 2023-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202105302PA (en) | Dll3-targeting multispecific antigen-binding molecules and uses thereof | |
IL287848A (en) | Multispecific antigen-binding molecules and uses thereof | |
SG11202104264TA (en) | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof | |
PT3818086T (en) | Treatment and prevention of cancer using her3 antigen-binding molecules | |
IL290299A (en) | Multispecific antigen-binding molecules for cell targeting and uses thereof | |
IL287765A (en) | Tigit and pd-1/tigit-binding molecules | |
SG11202105566TA (en) | Immune activating multispecific antigen-binding molecules and uses thereof | |
KR101882072B1 (en) | Field-effect transistors having transition metal dichalcogenide channels and methods of manufacture | |
EP4132969A4 (en) | Anti-mesothelin antigen-binding molecules and uses thereof | |
EP3586872A4 (en) | Pharmaceutical composition, antigen-binding molecules, treatment method, and screening method | |
EP3397262A4 (en) | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer | |
GB202017419D0 (en) | Structural analysis of ionised molecules | |
IL278832A (en) | Optimized gp41-binding molecules and uses thereof | |
IL283087A (en) | Multispecific binding constructs against checkpoint molecules and uses thereof | |
IL273761A (en) | Cysteine engineered antigen-binding molecules | |
IL276253A (en) | Bispecific antigen-binding molecules and methods of use | |
HK1245778A1 (en) | Small molecules for the treatment of primary cancer and cancer metastasis | |
GB201720426D0 (en) | CD47 and BCMA antigen-binding molecules | |
EP3753956A4 (en) | Antigen-binding molecule and combination | |
IL284781A (en) | Lilrb3-binding molecules and uses therefor | |
IL311096A (en) | Antigen-binding molecules and uses thereof | |
EP4114856A4 (en) | Antigen-binding molecules and uses thereof | |
AU2020900632A0 (en) | Antigen-binding molecules and uses thereof | |
IL285585A (en) | Fcmr-binding molecules and uses thereof | |
AU2019901803A0 (en) | Antigen-binding molecules and uses therefor |